The main body of data indicates that the KDM6A/UTX demethylase protein acts as a tumour suppressor, and that tumours lacking or carrying mutations in KDM6A may, in some cancers, be targeted with either EZH2 or BET inhibitors. This evidence concerns the gene KDM6A and neoplasm.